{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-038997","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.589186+00:00","generated_at":"2026-06-15T02:41:51.847089+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jasper Therapeutics Q1 net loss widens to $14.3M; de-prioritizes AML/MDS Phase 3","bullets":["Net loss of $14.3M in Q1 2023 vs $2.2M in Q1 2022, driven by increased R&D and warrant liability changes.","Cash and cash equivalents of $129.4M as of March 31, 2023, boosted by $101.4M net proceeds from January public offering.","De-prioritized Phase 3 development of briquilimab as conditioning for AML/high-risk MDS; now focusing on chronic spontaneous urticaria and low-intermediate risk MDS.","Announced positive clinical data from Phase I/II of briquilimab in sickle cell disease: all three patients engrafted, 100% donor myeloid chimerism at 60 days.","Strengthened board with Vishal Kapoor; appointed Daniel Adelman as Acting CMO."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-038997","json":"https://secwatch.observer/filing/0001213900-23-038997.json","markdown":"https://secwatch.observer/filing/0001213900-23-038997.md","text":"https://secwatch.observer/filing/0001213900-23-038997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/0001213900-23-038997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/ea178442-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:41:51.847089+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbe3e12b64f2a1979ed50937ab3e18292367f5ad","claim":"Jasper Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $14.3 million.","evidence_excerpt":"On May 12, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2023 and providing a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023038997/0001213900-23-038997-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $14.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}